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INTRODUCTION 
Gastrointestinal and breast carcinomas are the most common
cancers and are responsible for the largest numbers of cancer-
related deaths in the world (Greenlee et al, 2000; Ries et al, 2000).
However, therapeutic options for the treatment of patients with
these tumours are limited to 3 fundamental modalities: surgical
resection, radiation therapy and chemotherapy. Against advanced
carcinomas, therapeutic options are limited to radiation therapy
and chemotherapy, and these modalities do not yield results.
Cancer-specific immunotherapy may be expected to become a
novel treatment modality for gastrointestinal and breast carci-
nomas. 
Many genes coding tumour rejection antigens such as MAGE
(Van der Bruggen et al, 1991), BAGE (Boel et al, 1995) and GAGE
(Van den Eynde et al, 1995) have been isolated from melanoma
cell lines. These antigens are recognized by autologous cytotoxic
T-lymphocytes (CTLs), which are restricted by human leukocyte
antigen (HLA) class I molecules, and some antigenic peptides
have been identified (Van den Eynde et al, 1997). Furthermore,
these antigens are also reported to induce class II restricted T-cell
responses (Chaux et al, 1999; Manici et al, 1999). Some of these
antigens are expressed in various tumours of different histological
origins, but not in normal tissues other than testis. Therefore, these
antigens have been designated cancer-testis antigens (CTAs) (Gure
et al, 1997) and their characteristics make them promising candi-
dates for cancer-specific immunotherapy; clinical trials using
peptides such as MAGE-1 or MAGE-3 are in progress for malig-
nant melanoma (Mukherji et al, 1995; Marchand et al, 1995). 
We previously reported that MAGE-1 and MAGE-3 genes were
expressed in 62% and 57% of oesophageal carcinomas (Inoue et
al, 1997), 41% and 38% of gastric carcinomas (Inoue et al, 1995),
30% and 20% of colorectal carcinomas (Mori et al, 1996), 24%
and 31% of breast carcinomas (Fujie et al, 1997), and more than
65% of hepatocellular carcinomas (Tahara et al, 1999). We also
identified some MAGE gene-encoded peptides recognized by CTL
(Tanaka et al, 1997; Fujie et al, 1999). Based on these findings,
cancer-specific immunotherapy using the HLA class I restricted
MAGE peptide has already begun in our institute for the treatment
of gastrointestinal or breast carcinoma. Although this type of
therapy appears promising and has thus far resulted in few side
effects, application of this therapy is restricted by the tumour
expression of the MAGE gene and patient HLA type. 
Recently, a novel method has been established based on the
specific recognition of autologous sera of some cancer patients,
termed serological analysis of antigens by recombinant expression
cloning (SEREX) (Sahin et al, 1995). This new method permits
direct molecular determination of new tumour antigens that elicit
an IgG antibody response in tumour patients. The method has
enabled the discovery of several novel genes with tumour speci-
ficity, such as NY-ESO-1 (Chen et al, 1997), LAGE. (Lethe et al,
1998), SCP-1 (Türeci et al, 1998b), SSX (Türeci et al, 1996) and
CT7 (Chen et al, 1998). These antigens are also expected to
become new candidates for cancer-specific immunotherapy, but
little information is available on the comprehensive expression of
CTAs in a large number of samples of gastrointestinal and breast
carcinomas. In the present study, we compared the expression of
newly found CTA genes with that of the MAGE gene in gastroin-
testinal and breast carcinomas, and investigated which CTAs are
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intestinal and breast carcinomas. 
MATERIALS AND METHODS 
Cell lines 
The fibrosarcoma cell line HT1080 was kindly provided by the
Institute of Development, Aging and Cancer, Tohoku University,
Sendai, Japan. The gastric carcinoma cell line Ns-8, and the
choriocarcinoma cell lines SCH, were supplied by the Japanese
Cancer Research Bank, Tokyo, Japan. The melanoma cell lines
MZ-2, and LB-373-MEL, were kindly provided by Dr Bernard
Lethe, Ludwig Institute for Cancer Research Brussels Branch,
Bruxelles, Belgium. 
Tissue samples 
Tumour samples (46 oesophageal squamous cell carcinomas, 102
gastric adenocarcinomas, 98 colorectal adenocarcinomas, and 129
breast adenocarcinomas) and matched control samples of the
normal tissue located 5 cm away from the tumour edge were
frozen immediately in liquid nitrogen less than 5 min after surgical
resection and kept at –90˚C until RNA extraction. The surgical
samples were obtained from the Department of Surgery, Medical
Institute of Bioregulation, Kyushu University, Beppu, Department
of Surgery, Oita Prefectural Hospital, Oita, and the Department of
Surgery, Saitama Cancer Center, Saitama, Japan. 
Extraction of RNA and RT-PCR analysis 
The acid guanidium thiocyanate-phenol-chloroform extraction
procedure (Chomczynski and Sacchi, 1987) was used for extrac-
tion of total RNA. The cDNA was synthesized from 8.0 µ g of total
RNA as described previously (Inoue et al, 1995). The presence of
MAGE-1 and MAGE-3 cDNA in the reverse transcription products
was detected by polymerase chain reaction (PCR) amplification in
separate reactions, using oligonucleotide primers located in the
different exons of each gene (Weynants et al, 1994). The presence
of  NY-ESO-1,  LAGE-1,  SSX-1,  SSX-2,  SSX-4 and  SCP-1 were
determined by PCR amplification under the same conditions as
reported previously (Lethe et al, 1998, Türeci et al, 1998a, Türeci
et al, 1998b). Briefly a 1/100 aliquot of reverse transcription
products were amplified in a 30 µ l reaction mixture containing
10 nmoles of each dNTP (dATP, dTTP, dCTP, dGTP.), 1 µ l of each
oligonucleotide primer at 10 µ M, 3 µ l of 10 × PCR buffer
(Perkin–Elmer, Branchburg, NJ, USA), and 1 U of AmpliTaq
DNA polymerase (Perkin–Elmer). In the detection of SCP-1, 2 U
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Table 1 PCR amplification programs 
Gene Primers from 5′ to 3′ Temperature and duration Cycle No. Product. size 
Denaturation 
Annealing 
Extension 
MAGE-1 f CGGCCGAAGGAACCTGACCCAG 94˚C for 1 min 33 421 bp 
r GCTGGAACCCTCACTGGGTTGCC 72˚C for 1 min 
72˚C for 2 min 
MAGE-3 f TGGAGGACCAGAGGCCCCC 94˚C for 1 min 33 725 bp 
r GGACGATTATCAGGAGGCCTGC 72˚C for 1 min 
72˚C for 2 min 
MAGE-4 f GAGCAGACAGGCCAACCG 94˚C for 30 s 30 446 bp 
r AAGGACTCTGCGTCAGGC 68˚C for 30 s 
72 C for 30 s 
NY-ESO-1 f CGCCTGCTTGAGTTCTACCTC 94˚C for 1 min 30 218 bp 
r AGGGAAAGCTGCTGGAGACAG 59˚C for 1 min 
72˚C for 1 min 
LAGE-1 f GCAGGATGGAAGGTGCCC 94˚C for 1 min 28 399 bp 
r CTGGCCACTCGTGCTGGGA 62˚C for 1 min 
72˚C for 1 min 
SCP-1 f GAAGAAAGGATGTTGACACAAAT 94˚C for 1 min 42 487 bp 
r GTTTTTCCATAAGTGCTACCATT 54˚C for 1 min 
72˚C for 1 min 
SSX-1 f CTAAAGCATCAGAGAAGAGAAGC 94˚C for 1 min 32 422 bp 
r AGATCTCTTATTAATCTTCTCAGAAA 54˚C for 1 min 
72˚C for 1 min 
SSX-2 f GTGCTCAAATACCAGAGAAGATC 94˚C for 1 min 32 435 bp 
r TTTTGGGTCCAGATCTCTCGTG 54˚C for 1 min 
72˚C for 1 min 
SSX-4 f AAATCGTCTATGTGTATATGAAGC 94˚C for 1 min 32 415 bp 
r GGGTCGCTGATCTCTTCATAAAC 56˚C for 1 min 
72˚C for 1 min 
GAPDH f GTCAACGGATTTGGTCGTATT 94˚C for 1 min 24 540 bp 
r AGTCTTCTGGGTGGCAGTGAT 56˚C for 1 min 
72˚C for 1 min 
f: forward primer r: reverse primer.
BJOC 01-1974 713-720  20/8/01  4:20 pm  Page 714of AmpliTaq Gold (Perkin–Elmer) were substituted for AmpliTaq
DNA polymerase. The reaction mixtures were then subjected to
the appropriate PCR programmes as listed in Table 1. To confirm
the specificity of the PCR products of the genes, we cloned the
PCR product into pCRII vector (Invitrogen, San Diego, CA, USA)
and then sequenced the cDNA by using the chain-termination
DNA sequencing method. We then determined the nucleotide
sequence of representative samples of PCR products and
confirmed them to be identical to the expected fragments of cDNA
in each CTA gene. An 8 µ l aliquot of each PCR product was sepa-
rated on a 1.5% agarose gel and visualized with ethidium bromide
staining. The pattern of expression of the CTA genes was estab-
lished with reverse transcription-PCR (RT-PCR) assays by evalu-
ating the intensity of a band in agarose gels; if the band was
recognized, the case was positive. The integrity of the RNA was
confirmed by performing PCR amplification of each cDNA with
CTA expression in carcinomas 715
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Figure 1 Detection of NY-ESO-1, LAGE-1, SCP-1, SSX-1, SSX-2 and SSX-4 mRNA expression by RT-PCR in 2 representative cases of oesophageal
carcinoma (Cases E-1, 2), 7 cases of gastric carcinoma (Cases G-1–7), and 3 cases of breast carcinoma (Cases B-1–3). cDNA extracted from tumour tissue
(T) and paired normal tissue (N) was amplified in each case. Only tumour sites expressed CTA genes and there was no sample with expression of CTA genes
in a normal site. GAPDH mRNA expression is shown as the corresponding control in the lower panel. Only positive cases were chosen to be presented
BJOC 01-1974 713-720  20/8/01  4:20 pm  Page 715primers for the gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Tokunaga et al, 1987). 
Immunohistochemistry 
The primary antibodies used in this study were 57B and B9.8
mAb. Both were kindly provided by Dr GC Spagnoli (Kocher et al,
1995, Schultz et al, 2000). 57B mAb stains tumour tissues that
express  MAGE-4 (Landry et al, 2000), and B9.8 mAb stains
tumour tissues that express NY-ESO-1 (Schultz et al, 2000). Frozen
tumour sections were thawed, washed in PBS, fixed in formalin
and incubated overnight at 4˚C in the presence of hybridoma
supernatant from 57B or B9.8. For both preparations, bound anti-
bodies were visualized using a Dako LSAB Peroxidase Kit
(Dako), according to the manufacturer’s recommendations, and
cell nuclei were counterstained with hematoxylin. 
Clinico-pathologic data 
All data including sex, histology, tumour size, depth of tumour
invasion, lymph node metastasis, lymph vessel permeation,
vascular vessel permeation, and disease stage were obtained
from the clinical and pathologic records. Disease stage 
was classified according to the criteria proposed by the Japanese
Society of Oesophageal Disease (8th edn), the Japanese 
Research Society of Gastric Cancer (12th edn), the
Japanese Research Society of Colon Cancer (5th edn), and
the Japanese Breast Cancer Society (12th edn). Tumours with or
without expression of the CTA genes were then compared. 
Statistical analysis 
Statistical analysis was performed by the chi-square or Fisher’s
exact test. The level of significance was set at P < 0.05. 
RESULTS 
Expression of CTA genes: cultured cell lines and
clinical samples 
The expression of 6 CTA genes, NY-ESO-1, LAGE-1, SCP-1, SSX-
1, SSX-2 and SSX-4, was determined by RT-PCR analysis. Each
CTA was expressed in various types of carcinoma cell line. NY-
ESO-1 and SSX-4 were expressed in SCH, LAGE-1 in LB-373,
SCP-1 in Ns-8, SSX-1 in MZ-2, and SSX-2 in HT1080. These cell
lines were used as positive controls in each analysis. In clinical
samples, all 6 CTA genes were expressed exclusively in carcinoma
tissues. None of the 6 CTA genes were expressed in the paired
normal tissues (Figure 1). 
Frequency of expression of CTA genes in tumour
samples 
Expression of the 6 CTA genes was examined in 46 samples of
oesophageal carcinoma, 102 samples of gastric carcinoma, 98
samples of colorectal carcinoma, and 129 samples of breast carci-
noma. There was no CTA gene expressed more frequently than the
MAGE-1 and MAGE-3 genes. We found relatively high expression
of LAGE-1 (39.1%) in oesophageal carcinoma, SCP-1 (23.5%)
and SSX-4 (20.6%) in gastric carcinoma, and SCP-1 (34.1%) in
breast carcinoma, while we found high expression of none of the
CTA genes including MAGE-1 and MAGE-3 in colorectal carci-
noma. Table 2 summarizes the results of RT-PCR analysis of the
CTA gene expression. 
Expression of the 6 CTA genes correlated with none of the
clinico-pathological parameters examined. There was no signifi-
cant relationship between the expression of the 6 CTAs and clin-
ical parameters for any type of carcinoma (data not shown). 
Synchronous expression of multiple CTA genes in the
same tumour sample 
Next, we analyzed multiple expression of the 8 CTA genes
including MAGE-1 and MAGE-3 in each case. As shown in Figure
2A, synchronous expression of MAGE-1,  MAGE-3,  NY-ESO-1,
and LAGE-1 were detected in a clinical sample of oesophageal
carcinoma (Case E-1). Oesophageal carcinoma expressed 2.1
CTA genes on average, the largest number among the 4 types of
carcinomas examined in this study. In oesophageal carcinoma, 39
(84.7%) of 46 samples expressed at least 1 CTA gene and 28
(60.9%) of 46 samples expressed at least 2 CTA genes synchro-
nously. In colorectal carcinoma, 25 (20.4%) of 98 samples
expressed at least 1 CTA gene, and only 5 (5.1%) of 98 samples
expressed multiple CTA genes synchronously. The results for
gastric and breast carcinoma are summarized in Figure 2B. 
Synchronous expression of CTA genes with MAGE
genes 
We analyzed the synchronous expression of CTA genes with
MAGE-1 or  MAGE-3 gene. A total of 18 (46.2%) of 39
oesophageal carcinoma samples expressed LAGE-1 with synchro-
nous expression of MAGE-1 or MAGE-3 genes, 21 (46.7%) of 45
gastric carcinomas synchronously expressed SSX-4, and 18
716 K Mashino et al
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Table 2 Expression of CTA genes in gastrointestinal and breast carcinomas 
NY-ESO-1 (%) LAGE-1 (%) SCP-1 (%) SSX-1 (%) SSX-2 (%)  SSX-4 
Oesophageal carcinoma 11 18 1 0 0  6 
n = 46 (23.9) (39.1) (2.2)  (0) (0) (13.0) 
Gastric carcinoma 8 12 24 3 3  21 
n = 102 (7.8) (11.8) (23.5)  (2.9) (2.9) (20.6) 
Colorectal carcinoma 2 3 0 0 2  2 
n = 98 (2.0) (3.1) (0) (0)  (2.0) (2.0) 
Breast carcinoma 13 4 44 1 5  12 
n = 129 (10.1) (3.1) (34.1)  (0.8) (3.9) (9.3) 
BJOC 01-1974 713-720  20/8/01  4:20 pm  Page 716(38.3%) of 47 breast carcinomas synchronously expressed SCP-1.
We also analysed the cases with expression of neither MAGE-1 nor
MAGE-3 genes to determine targets for cancer immunotherapy
other than MAGE genes. A total of 26 (31.7%) of 82 samples of
breast carcinoma and 12 (21.1%) of 57 samples of gastric carci-
noma expressed the SCP-1 gene, with expression of neither
MAGE-1 nor MAGE-3. These results are summarized in Figure 3. 
Differential distribution of carcinoma cells staining with
CTA protein-specific mAbs in carcinoma tissues 
We investigated the distribution of carcinoma cells expressing
CTA proteins in tumour tissues by immunohistochemical analysis
for representative cases. The primary antibodies used in this study
were 57B, a murine mAb against MAGE-4 protein (Landry et al,
CTA expression in carcinomas 717
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Figure 2 (A) Synchronous expression of multiple CTA genes in the oesophageal and breast carcinoma cases detected by RT-PCR. Case E-3, oesophageal
carcinoma with expression of MAGE-1, MAGE-3, NY-ESO-1, and LAGE-1. Case B-4, breast carcinoma with expression of MAGE-3, MAGE-4, NY-ESO-1, and
SSX-4. cDNA extracted from tumour tissue (T) and paired normal tissue (N) were amplified in each case. (B) Expression of 8 CTA genes (MAGE-1, MAGE-3,
NY-ESO-1, LAGE-1, SCP-1, SSX-1, SSX-2, SSX-4) in 46 oesophageal carcinomas, 102 gastric carcinomas, 98 colorectal carcinomas, and 129 breast
carcinomas. Number of CTA genes expressed per clinical sample is summarized. Synchronous expression of multiple CTA genes was detected in 28 (61%) of
46 oesophageal carcinoma samples, 34 (33%) of 102 gastric carcinoma samples and 34 (26%) of 129 breast carcinoma samples
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(Schultz et al, 2000). Case B-4 was one of breast carcinoma, in
which MAGE-3, MAGE-4, NY-ESO-1, and SSX-4 were detected in
RT-PCR analysis (Figure 2A). Heterogeneity of 57B and B9.8
staining was detected in the tumour specimens of Case B-4. The
staining, which was mostly detectable in the cell cytoplasm,
appeared to be limited to carcinoma cells. The tumour cells 
stained with 57B and B9.8 revealed the differential distribution of
MAGE-4 and NY-ESO-1 in breast carcinoma tissues (Figure 4).
We examined 5 cases expressing both MAGE-4 and NY-ESO-1
genes and revealed the differential distribution in 2 cases and the
same distribution in 3 cases. 
DISCUSSION 
In our institute, clinical trials of cancer-specific immunotherapy
have been ongoing on patients with gastrointestinal carcinomas,
using antigen-presenting cells pulsed with MAGE peptides. Good
results were observed in some clinical cases, but there are two
problems that need to be solved. One of the problems is the restric-
tion of candidates for immunotherapy. The prerequisite for therapy
is MAGE gene expressions in tumour tissues and adaptation of
patient HLA type to peptide-binding specificity. Another is the
heterogeneous expression pattern of MAGE, which may be a
strategy for evasion of immunosurveillance by malignant cells
(Jungbluth et al, 2000; Sadanaga et al, 1999). In the present study,
we found 3 novel possibilities for a solution of these problems. 
First, we found high expression of CTAs other than MAGE-1 or
MAGE-3 in gastric and oesophageal carcinomas. We found high
expression of SCP-1 (23%) and SSX-4 (20%) genes in gastric
carcinoma and of NY-ESO-1 (19%) and LAGE-1 (38%) genes in
oesophageal carcinoma. High expression of SSX genes was
detected in a wide variety of neoplasms such as head and neck
carcinomas, colorectal carcinoma, and breast carcinoma (Türeci
et al, 1998a). We also found high expression of SSX-4 in the
gastric carcinoma, in which either the MAGE-1 or MAGE-3 gene
was co-expressed. These findings suggest that these antigens
might be targets for cancer-specific immunotherapy in addition to
MAGE-1 and MAGE-3. NY-ESO-1 and  LAGE-1 were also
reported to be expressed in a large number of breast carcinomas
(Chen et al, 1997; Lethe et al, 1998), but we could not detect a high
rate of expression of either gene in breast carcinomas. These
differences might potentially contribute to the disparity in survival
rate after breast cancer among the various races (Dignam, 2000). 
Secondly, we found high expression of SCP-1 in cases
expressing neither MAGE-1 nor MAGE-3 in gastric and breast
carcinomas. The SCP-1 gene was expressed in 26 (31.7%) of the
82 samples of breast carcinoma expressing neither MAGE-1 nor
MAGE-3, and was expressed in 12 (21.2%) of 57 samples of
gastric carcinoma expressing neither MAGE-1 nor MAGE-3. In
718 K Mashino et al
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MAGE-3 in breast carcinoma. These results suggest that if SCP-1
is a new target antigen in addition to MAGE-1 and MAGE-3, the
candidates for CTA-based cancer immunotherapy for gastric and
breast carcinomas will be increased in number. SCP-1 was identi-
fied as HOM-TES-14, during screening of a cDNA library
enriched for testis-specific clones with serum from a renal cell
carcinoma patient (Türeci et al, 1998b). High levels of expression
of SCP-1 in tumour tissue and normal testis are recognized at the
mRNA and protein levels by RT-PCR and Western blot analysis,
respectively. The antigenic peptides encoded by these CTAs will
be identified in future studies. Patients’ opportunities for cancer-
specific immunotherapy can thus be expanded. 
Thirdly, we found a high frequency of synchronous expression
of multiple CTA genes in clinical tumour samples. At least 2 CTA
genes were expressed in 28 (61%) of 46 oesophageal carcinomas,
34 (33%) of 102 gastric carcinomas, and 34 (26%) of 129 breast
carcinomas (Figure 3). In the present study, we examined repre-
sentative samples of breast carcinoma with immunohistochemical
analysis of 57B or B9.8 antibodies. Antibody 57B stains the
tumours that express the MAGE-4 gene, and antibody B9.8 recog-
nized tumours that expressed the NY-ESO-1 gene (Landry et al,
2000; Schultz et al, 2000). As shown in Figure 2A and Figure 4,
Case B-4 expressed both MAGE-4 and NY-ESO-1, and immuno-
histochemical analysis revealed differential distribution of MAGE-
4-or NY-ESO-1-positive carcinoma cells. We and others have
reported heterogeneous expression of MAGE genes in tumour
tissues using immunohistochemical analysis (Jungbluth et al,
2000; Sadanaga et al, 1999). In this study, we found the heteroge-
neous expression of MAGE-4 and NY-ESO-1 in carcinoma
tissues, indicating that some parts of carcinoma cells were stained
with 57B antibody, and others with B9.8 antibody (Figure 4). This
differential distribution of staining of carcinoma cells indicates
that the area of carcinoma cells expressing tumour rejection anti-
gens might be enlarged. Therefore, in this case, a combined vacci-
nation based on both MAGE-4 and NY-ESO-1 may cause
immunological reactions in a larger area of tumour tissues than a
single peptide-based vaccination. Taken together, our findings
suggest that polyvalent vaccinations with multiple antigens might
be necessary to obtain good clinical results in cancer
immunotherapy. 
Despite shared expression of multiple CTAs in tumour species,
individual antigens exhibit distinct variation in quantity.
Immunohistochemical analysis revealed heterogeneous expres-
sion, and RT-PCR analysis revealed distinct intensity of a band in
agarose gels. It is important to evaluate the quantity of expression
of each antigen when use of immunotherapy is decided. 
In conclusion, the predominant expression of NY-ESO-1 and
LAGE-1 in oesophageal carcinoma, SSX-4 and SCP-1 in gastric
carcinoma and SCP-1 in breast carcinoma suggest possible targets
for cancer-specific immunotherapy in addition to MAGE-1 and
MAGE-3. Furthermore, SCP-1 could be a novel target for patients
CTA expression in carcinomas 719
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Figure 4 Immunohistochemical and RT-PCR analysis of cases expressing multiple CTAs. As shown in Figure 2A, RT-PCR analysis revealed synchronous
expression of MAGE-3, MAGE-4, NY-ESO-1, and SSX-4 in this breast carcinoma case, Case B-4. Immunohistochemical staining with 57B and B9.8,
consecutive sections of Case B-4 (A–F). The upper panels show NY-ESO-1 protein immunoreactivity of B9.8 mAb (C) was detected in the carcinoma cells not
expressing the MAGE-4 gene product (B). The lower panels show MAGE-4 protein immunoreactivity of 57B (E) was detected in the carcinoma cells not
expressing NY-ESO-1 gene product (F). Haematoxylin-eosin staining of the sections is shown in (A) and (D). (Original magnification × 200) 
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breast carcinomas. We also demonstrate the possibility that poly-
valent vaccination with multiple CTA genes will yield effective
clinical results for cancer-specific immunotherapy. 
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